The recent phase-II controlled study on ABT-414 in the treatment of EGFR amplified recurrent GBM (NTELLANCE 2; NCT02343406) has suggested a possible role of this agent (in combination with temozolomide) in the treatment of this tumor. This evidence concerns the gene EGFR and glioblastoma.